IBI376

DRUG2 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd., Chinese PLA General Hospital

Conditions

Indolent Non-hodgkin LymphomaInert Non Hodgkin's Lymphoma

Phase 2

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

CompletedNCT04298879

Innovent Biologics (Suzhou) Co. Ltd.Indolent Non-hodgkin Lymphoma

Start: 2020-04-07End: 2023-11-21Updated: 2024-06-05

IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.

Chinese PLA General HospitalInert Non Hodgkin's Lymphoma

Start: 2021-12-31End: 2024-11-01Target: 40Updated: 2023-05-12

Related Papers

Safety and Efficacy of Parsaclisib in Combination with Rituximab in Patients with Previously Untreated Indolent B-Cell Lymphoma: Primary Analysis from a Phase 2 Study (REPLY)

Blood2023-11-02

P1099: A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF PARSACLISIB, A PI3KΔ INHIBITOR, IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN CHINA: UPDATED RESULTS FROM THE STUDY

HemaSphere2023-08-01

A phase II, multicenter, single-arm study of parsaclisib, a PI3Kδ inhibitor, in relapsed or refractory follicular lymphoma in China: Updated data from the study.

Journal of Clinical Oncology2022-06-01

A Phase II, Multicenter, Single-Arm, Open-Label Study of Parsaclisib, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma in China

Blood2021-11-05